ACXP: Acurx Pharmaceuticals, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
19 institutions reported holding $185K of Acurx Pharmaceuticals, Inc. on Form 13F (21 the quarter before). 2 opened a new position and 4 sold out. Shares held by institutions: -26%.
| Largest holders | Shares | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 31,099 | $48K |
| GEODE CAPITAL MANAGEMENT, LLC | 26,411 | $41K |
| VANGUARD FIDUCIARY TRUST CO | 16,205 | $25K |
| JANE STREET GROUP, LLC | 15,727 | $24K |
| Prospect Financial Services LLC | 13,785 | $21K |
| MORGAN STANLEY | 7,500 | $12K |
| Tower Research Capital LLC (TRC) | 2,744 | $4K |
| WELLS FARGO & COMPANY/MN | 2,300 | $4K |
| Westside Investment Management, Inc. | 1,650 | $3K |
| LANARK FINANCIAL, INC. | 1,500 | $2K |
Clinical trial readouts
1 Phase 2 or 3 trials by Acurx Pharmaceuticals, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-09-29 (est.) | Ibezapolstat | Clostridium Difficile Infection Recurrence | Phase 2 | 20 | Recruiting | NCT07513285 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.